

TAKAFULINK DANA EKUITI GLOBAL

All information as at 30 September 2024 unless otherwise stated


Semua maklumat adalah seperti pada 30 September 2024 melainkan jika dinyatakan

Objective / Objektif Dana

Takafulink Dana Ekuiti Global aims to provide capital appreciation by investing in Shariah-compliant investments with exposure to the global equity markets.

Takafulink Dana Ekuiti Global bertujuan untuk menyediakan peningkatan nilai modal dengan melabur dalam sekuriti patuh Syariah melalui pendedahan terhadap pasaran ekuiti global.

Where the Fund invests Komposisi Pelaburan Dana



Asset Allocation Peruntukan Aset


	% NAV
1 abrdn Islamic World Equity Fund	98.68
2 Cash, Deposits & Others	1.32

Fund Details / Maklumat Terperinci Dana

Investment Manager / Pengurus Pelaburan	Prudential BSN Takaful Berhad
Inception Date / Tarikh Diterbitkan	08/07/2019
Current Fund Size / Saiz Dana Terkini	RM36,306,157.21
Annual Fund Management Charge / Caj Pengurusan Dana Tahunan	1.5% p.a.
Current NAV / NAB Terkini	RM1.50081

How the Fund has performed / Prestasi Dana

Performance Graph / Jaduan Prestasi Dana
Takafulink Dana Ekuiti Global Vs. MSCI ACWI Islamic (Shariah) Index



Total Price Movement Over the Following Periods / Jumlah Pergerakan Harga Dalam Tempoh Tersebut

	1 month	3 months	6 months	1 year	3 years	5 years	Since Inception
Price Movement / Pergerakan Harga	-4.02%	-8.47%	-8.26%	8.02%	4.85%	49.58%	50.08%
Benchmark / Penanda Aras	-2.79%	-9.37%	-9.00%	6.14%	24.68%	68.09%	67.74%
Outperformance / Perbezaan Prestasi	-1.23%	0.90%	0.74%	1.88%	-19.83%	-18.51%	-17.66%

TAKAFULINK DANA EKUITI GLOBAL

All information as at 30 September 2024 unless otherwise stated

Semua maklumat adalah seperti pada 30 September 2024 melainkan jika dinyatakan

Monthly Update / Laporan Bulanan Terkini

Fund Review & Strategy

The Fund returned -4.02% for the month, underperforming the benchmark return of -2.79% by 1.23%. Year-to-date, The Fund returned 0.26%, outperforming the benchmark return of -1.07% by 1.33%. After a sell-off at the start of the month due to continued weakness in the US manufacturing sector and the labour market, global equities steadily recovered. Consumer and producer price inflation data in the US reinforced the existing disinflation narrative. After the US Federal Reserve (Fed) significantly lowered interest rates in September, investors are now factoring in the certainty of further cuts at the central bank's next meetings in November and December. The People's Bank of China announced its largest stimulus package since the pandemic, with a raft of planned monetary support measures. Looking at stock drivers, Adobe was among the main laggards. Its results were above expectations on most key metrics. However, its fourth quarter outlook for top line growth was below expectations, driving the shares lower. Novo Nordisk's shares declined on disappointing data from a Phase II trial of its experimental drug, Monlunabant, as well as concerns around meeting third quarter earnings expectations. More positively, Clicks Group added value, although there was little stock specific news. Divestment of Unicorn Pharmaceuticals could pave the way for the Department of Health to issue Clicks new pharmacy licences, which, in turn, should support new store roll out. The Target Fund Manager started a position in Volttronic, a vertically integrated industrial company specialising in offline and online uninterrupted power supply equipment and inverters. The company has a very strong position, competing against a fragmented set of much smaller competitors. Following a period of destocking activity last year, they believe that underlying growth trends are set to resume and that the company can continue to gradually take market share in its end markets. The Target Fund Manager exited AstraZeneca and TSMC as they are no longer included in the benchmark.

Tinjauan & Strategi Dana

Dana memberikan pulangan sebanyak -4.02% pada bulan ini, tidak mengatasi pulangan penanda aras -2.79% dengan perbezaan 1.23%. Sejak awal tahun sehingga bulan tinjauan, Dana memperoleh pulangan sebanyak 0.26%, mengatasi pulangan penanda aras -1.07% dengan perbezaan 1.33%. Selepas penjualan di awal bulan yang disebabkan oleh kelemahan berterusan sektor pembuatan dan pasaran buruh di AS, ekuiti global pulih dengan mantap. Data inflasi harga pengguna dan pengeluar di AS mengukuhkan naratif disinflasi sedia ada. Selepas Rizab Persekutuan AS (Fed) menurunkan kadar faedah dengan ketara pada September, pelabur kini memfaktorkan kepastian berkenaan pemotongan selanjutnya sewaktu mesyuarat bank pusat tersebut pada November dan Disember akan datang. Bank Rakyat China mengumumkan pakej rangsangan terbesarnya sejak pandemik, dengan pelbagai langkah sokongan kewangan terancang. Merujuk kepada pemacu saham, Adobe adalah antara yang ketinggalan paling banyak. Keputusannya melebihi jangkaan pada kebanyakan metrik utama. Walau bagaimanapun, tinjauan suku keempatnya untuk pertumbuhan barisan teratas adalah di bawah jangkaan, lalu memacu saham ke paras yang lebih rendah. Saham Novo Nordisk merosot berikutan data yang mengecewakan daripada percubaan Fasa II ubat eksperimennya, Monlunabant, di samping kebimbangan untuk memenuhi jangkaan pendapatan suku ketiga. Clicks Group menambah nilai, meskipun terdapat sedikit berita khusus tentang saham. Penjualan Unicorn Pharmaceuticals boleh membuka jalan kepada Jabatan Kesihatan untuk mengeluarkan lesen farmasi baharu Clicks, yang selepas itu sepatutnya menyokong pelancaran kedai baharu. Pengurus Dana Sasaran memulakan pegangan dalam Volttronic, sebuah syarikat perindustrian bersepadu menegak yang mengkhusus dalam peralatan dan penyongsang bekalan kuasa tanpa gangguan di luar talian dan dalam talian. Syarikat ini mempunyai kedudukan yang sangat kukuh, bersaing dengan kumpulan pesaing yang lebih kecil dan berpecah-belah. Berikutan tempoh aktiviti nyah stok tahun lepas, Pengurus Dana Sasaran percaya bahawa aliran pertumbuhan asas bersedia untuk disambung semula dan syarikat tersebut boleh terus membesarkan lagi bahagian pasaran akhir secara beransur-ansur. Pengurus Dana Sasaran keluar dari AstraZeneca dan TSMC kerana kedua-duanya tidak lagi termasuk dalam penanda aras.

Source / Sumber: Fund Commentary, September 2024, N/A

Disclaimer

Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units may fall as well as rise. Past performances of the funds and that of the fund managers are not necessarily indicative of future performance. The price movements indicated are not reflective of the actual return on your investments (which are subject to your premium allocation rate and deduction charges). The actual return on your invested premiums may fluctuate based on the underlying performance of the investment-linked funds. All Takafulink Dana are invested in Shariah-approved securities and/or Islamic private debt securities. This leaflet is for illustrative purposes only. For further details on the terms and conditions, please refer to the policy document. For further details on how you can invest in these funds, please refer to the respective product brochures. In the event of discrepancy between the information in this fact sheet and the policy document, the information in the policy document shall prevail.

Pelaburan adalah tertakluk kepada risiko-risiko pelaburan termasuk kemungkinan kehilangan jumlah wang pokok yang dilabur. Nilai unit mungkin naik ataupun jatuh. Prestasi masa dulu dana-dana atau pengurus-pengurus dana tidak semestinya mencerminkan prestasi masa depan. Pergerakan harga yang ditunjukkan tidak menggambarkan pulangan sebenar pelaburan anda (yang tertakluk kepada kadar peruntukan premium dan caj potongan). Pulangan sebenar ke atas premium yang anda labur mungkin berbeza, bergantung kepada prestasi dana-dana). Semua Takafulink Dana dilaburkan dalam sekuriti yang diluluskan oleh Syariah dan/atau sekuriti hutang swasta Islam. Risalah ini disediakan hanya untuk gambaran semata-mata. Sila rujuk kepada dokumen polisi untuk keterangan lanjut mengenai terma-terma dan syarat-syarat. Untuk keterangan lanjut mengenai bagaimana anda boleh melabur dalam dana-dana ini, sila rujuk kepada risalah-risalah produk yang berkenaan. Jika terdapat perbezaan di antara helaian fakta dan dokumen polisi, maklumat dalam dokumen polisi dianggap muktamad.

PRUDENTIAL BSN

TAKAFUL